179 related articles for article (PubMed ID: 24851115)
1. Strategies for Early Non-response to Antipsychotic Drugs in the Treatment of Acute-phase Schizophrenia.
Hatta K; Ito H
Clin Psychopharmacol Neurosci; 2014 Apr; 12(1):1-7. PubMed ID: 24851115
[TBL] [Abstract][Full Text] [Related]
2. Practical pharmacotherapy for acute schizophrenia patients.
Hatta K
Psychiatry Clin Neurosci; 2015 Nov; 69(11):674-85. PubMed ID: 26037685
[TBL] [Abstract][Full Text] [Related]
3. Switching and augmentation strategies for antipsychotic medications in acute-phase schizophrenia: latest evidence and place in therapy.
Hatta K; Sugiyama N; Ito H
Ther Adv Psychopharmacol; 2018 Jun; 8(6):173-183. PubMed ID: 29854396
[TBL] [Abstract][Full Text] [Related]
4. Antipsychotic treatment strategies for acute phase and treatment resistance in schizophrenia: A systematic review of the guidelines and algorithms.
Shimomura Y; Kikuchi Y; Suzuki T; Uchida H; Mimura M; Takeuchi H
Schizophr Res; 2021 Oct; 236():142-155. PubMed ID: 34509129
[TBL] [Abstract][Full Text] [Related]
5. Antipsychotic polypharmacy in schizophrenia: benefits and risks.
Barnes TR; Paton C
CNS Drugs; 2011 May; 25(5):383-99. PubMed ID: 21476610
[TBL] [Abstract][Full Text] [Related]
6. Real-world effectiveness of antipsychotic monotherapy and polytherapy in 1543 patients with acute-phase schizophrenia.
Hatta K; Hasegawa H; Imai A; Sudo Y; Morikawa F; Katayama S; Watanabe H; Ishizuka T; Nakamura M; Misawa F; Fujita K; Ozaki S; Umeda K; Nakamura H; Sawa Y; Sugiyama N;
Asian J Psychiatr; 2019 Feb; 40():82-87. PubMed ID: 30772732
[TBL] [Abstract][Full Text] [Related]
7. Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments (SMART-CAT) in first-episode schizophrenia patients: Rationale and trial design.
Li X; Guo X; Fan X; Feng T; Wang C; Yao Z; Xu X; Chen Z; Wang H; Xie S; He J; Zhuo K; Xiang Q; Cen H; Wang J; Smith RC; Jin H; Keshavan MS; Marder SR; Davis JM; Jiang K; Xu Y; Liu D
Schizophr Res; 2021 Apr; 230():87-94. PubMed ID: 33279374
[TBL] [Abstract][Full Text] [Related]
8. A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation.
Stahl SM; Grady MM
Curr Med Chem; 2004 Feb; 11(3):313-27. PubMed ID: 14965234
[TBL] [Abstract][Full Text] [Related]
9. Maximizing response to first-line antipsychotics in schizophrenia: a review focused on finding from meta-analysis.
Smith RC; Leucht S; Davis JM
Psychopharmacology (Berl); 2019 Feb; 236(2):545-559. PubMed ID: 30506237
[TBL] [Abstract][Full Text] [Related]
10. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.
Kane JM; Leucht S; Carpenter D; Docherty JP;
J Clin Psychiatry; 2003; 64 Suppl 12():5-19. PubMed ID: 14640142
[TBL] [Abstract][Full Text] [Related]
11. Antipsychotic switching versus augmentation among early non-responders to risperidone or olanzapine in acute-phase schizophrenia.
Hatta K; Otachi T; Fujita K; Morikawa F; Ito S; Tomiyama H; Abe T; Sudo Y; Takebayashi H; Yamashita T; Katayama S; Nakase R; Shirai Y; Usui C; Nakamura H; Ito H; Hirata T; Sawa Y;
Schizophr Res; 2014 Sep; 158(1-3):213-22. PubMed ID: 25086659
[TBL] [Abstract][Full Text] [Related]
12. The risks and benefits of switching patients with schizophrenia or schizoaffective disorder from two to one antipsychotic medication: a randomized controlled trial.
Constantine RJ; Andel R; McPherson M; Tandon R
Schizophr Res; 2015 Aug; 166(1-3):194-200. PubMed ID: 26141142
[TBL] [Abstract][Full Text] [Related]
13. Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis.
Galling B; Roldán A; Hagi K; Rietschel L; Walyzada F; Zheng W; Cao XL; Xiang YT; Zink M; Kane JM; Nielsen J; Leucht S; Correll CU
World Psychiatry; 2017 Feb; 16(1):77-89. PubMed ID: 28127934
[TBL] [Abstract][Full Text] [Related]
14. The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses.
Haddad PM; Correll CU
Ther Adv Psychopharmacol; 2018 Nov; 8(11):303-318. PubMed ID: 30344997
[TBL] [Abstract][Full Text] [Related]
15. Antipsychotic response in first-episode schizophrenia: efficacy of high doses and switching.
Agid O; Schulze L; Arenovich T; Sajeev G; McDonald K; Foussias G; Fervaha G; Remington G
Eur Neuropsychopharmacol; 2013 Sep; 23(9):1017-22. PubMed ID: 23706529
[TBL] [Abstract][Full Text] [Related]
16. Atypical antipsychotics for psychosis in adolescents.
Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
[TBL] [Abstract][Full Text] [Related]
17. [Antipsychotics in bipolar disorders].
Vacheron-Trystram MN; Braitman A; Cheref S; Auffray L
Encephale; 2004; 30(5):417-24. PubMed ID: 15627046
[TBL] [Abstract][Full Text] [Related]
18. Amisulpride augmentation in clozapine-unresponsive schizophrenia (AMICUS): a double-blind, placebo-controlled, randomised trial of clinical effectiveness and cost-effectiveness.
Barnes TR; Leeson VC; Paton C; Marston L; Davies L; Whittaker W; Osborn D; Kumar R; Keown P; Zafar R; Iqbal K; Singh V; Fridrich P; Fitzgerald Z; Bagalkote H; Haddad PM; Husni M; Amos T
Health Technol Assess; 2017 Sep; 21(49):1-56. PubMed ID: 28869006
[TBL] [Abstract][Full Text] [Related]
19. Pharmacotherapy of treatment-resistant schizophrenia: a clinical perspective.
Dold M; Leucht S
Evid Based Ment Health; 2014 May; 17(2):33-7. PubMed ID: 24713315
[TBL] [Abstract][Full Text] [Related]
20. [Clinical and socio-demographic profile of patients with schizophrenia according to the antipsychotic treatment prescribed].
Lamarque I; Auffray L; Villamaux M; Demant JC; Launay C; Petitjean F; Salomé F
Encephale; 2006; 32(3 Pt 1):369-76. PubMed ID: 16840931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
